1. Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH 
Sandra Habbig, MD, Carsten Bergmann, MD, Lutz T. Weber, MD 
American Journal of Kidney Diseases 
Volume 67, Issue 3, Pages (March 2016)
DOI: /j.ajkd
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Prompt response to eculizumab treatment and stable remission after discontinuation of treatment in a patient with atypical hemolytic uremic syndrome due to a mutation in CFH, the gene encoding complement factor H. Abbreviation: LDH, lactate dehydrogenase.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2016 National Kidney Foundation, Inc. Terms and Conditions